Novel BMP2 antagonist inhibitors for bone graft substitution
Recombinant bone morphogenetic protein 2 (BMP-2) is a known bone graft substitute used in the treatment of bone fractures and bone defects and is currently available on the market. BMP-2 must be applied in high concentrations to induce bone formation in clinical settings. Its limited therapeutic efficacy may be due to the presence of BMP antagonists that neutralize exogenous BMP-2. Inventors at the University of Würzburg (Germany) have identied a novel inactive BMP-2 mutein, named L51P, which acts as an inhibitor of BMP antagonists noggin, chordin and gremlin. In vitro and in vivo validation studies with a combination of BMP-2 and L51P led to a signi cant increase in BMP activity.
BMP-2 and other members of the TGF-b superfamily regulate the development, maintenance and regeneration of many tissues and organs. Dysregulation of BMP and TGF-b signalling is critical during several disorders including fibrosis, osteoporosis, cancer, arthritis and bone or cartilage repair.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Superradiant atoms could push the boundaries of how precisely time can be measured
Superradiant atoms can help us measure time more precisely than ever. In a new study, researchers from the University of Copenhagen present a new method for measuring the time interval,…
Ion thermoelectric conversion devices for near room temperature
The electrode sheet of the thermoelectric device consists of ionic hydrogel, which is sandwiched between the electrodes to form, and the Prussian blue on the electrode undergoes a redox reaction…
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…